All good. Credit where credit is due. You have been more right than me on this one so far. Your focus on the CN was a reminder to me to alway look a lot deeper into company balance sheets.
Anyhow, IMO this company has had and still has some issues. But IMO we have turned the corner. If we could get some improved communication in terms of articulating where the business is and where it's going then maybe more investors will take note. I have explained my reasons in detail as how I see the state of play. And maybe it will take an extra 6 months as revenue final hit the bank account for the market to revalue accordingly.
For me, this ticks a lot of boxes and the risk reward for a small cap m tech stock is looking very good. As said, I will continue to add to my position.
- Forums
- ASX - By Stock
- GMV
- Ann: Trading Halt
Ann: Trading Halt, page-89
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online